Jinhe Biotechnology Co. Ltd.
SHZ: 002688.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Changxian Xie
- Employees
- 2,316
- Headquarters
- Dalian, China
- IPO year
- 2012
- Market cap
- CN¥4.6B
- Website
- https://www.jinhe.com.cn
Loading 002688…
Loading profile data…Frequently asked questions about 002688
What does Jinhe Biotechnology Co. Ltd. (002688.SZ) do?
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and...
Where does 002688.SZ trade?
Jinhe Biotechnology Co. Ltd. (002688.SZ) trades on the Shenzhen Stock Exchange.
What sector is 002688.SZ in?
Jinhe Biotechnology Co. Ltd. (002688.SZ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Jinhe Biotechnology Co. Ltd.?
Changxian Xie is the chief executive officer of Jinhe Biotechnology Co. Ltd. (002688.SZ).
Where is Jinhe Biotechnology Co. Ltd. headquartered?
Jinhe Biotechnology Co. Ltd. is headquartered in China.
Does 002688.SZ pay a dividend?
Yes — Jinhe Biotechnology Co. Ltd. (002688.SZ) paid a trailing twelve-month dividend of CNY 0.10 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 002688.SZ go public?
Jinhe Biotechnology Co. Ltd. (002688.SZ) completed its initial public offering in 2012.